Voriconazole interaction with class: Analgesics

sort by: interaction ascending



Interaction with Buprenorphine

Monitor therapy
QT risk: Voriconazole Buprenorphine

Effect: Voriconazole may increase the plasma concentrations of buprenorphine.

Clinical management: Caution should be exercised upon coadministration of these drugs. Monitor for increased buprenorphine toxicity.

Probable mechanism: Inhibition of the cytochrome P450 (CYP) 3A4-mediated biotransformation by voriconazole.

Summary: Although coadministration of voriconazole and buprenorphine has not been studied, in vitro data show that buprenorphine is a substrate of CYP3A4. Coadministration with the CYP3A4 inhibitor voriconazole may increase plasma concentrations of buprenorphine.


QT effect

Voriconazole: Conditional QT risk

Substantial evidence reports that this drug causes QT prolongation and has a risk of TdP, but only under certain known conditions (e.g. excessive dose, drug interaction, etc.).


Buprenorphine: Possible QT risk

Substantial evidence reports that this drug prolongs the QT interval and has a risk of causing TdP (when used as directed in labeling).